期刊文献+

Reversible lesions in the brain parenchyma in Wilson's disease confirmed by magnetic resonance imaging:earlier administration of chelating therapy can reduce the damage to the brain 被引量:2

下载PDF
导出
摘要 The aim of this study was to evaluate the resolution of brain lesions in patients with Wilson’s disease during the long-term chelating therapy using magnetic resonance imaging and a possible signiifcance of the time latency between the initial symptoms of the disease and the introduction of this therapy. Initial magnetic resonance examination was performed in 37 patients with proven neurological form of Wilson’s disease with cerebellar, parkinsonian and dystonic presentation. Magnetic resonance reexamination was done 5.7 ± 1.3 years later in 14 patients. Patients were divided into: group A, where chelating therapy was initiated 〈 24 months from the ifrst symp-toms and group B, where the therapy started≥ 24 months after the initial symptoms. Symmetry of the lesions was seen in 100% of patients. There was a signiifcant difference between groups A and B regarding complete resolution of brain stem and putaminal lesions (P= 0.005 andP=0.024, respectively). If the correct diagnosis and adequate treatment are not established less than 24 months after onset of the symptoms, irreversible lesions in the brain parenchyma could be ex-pected. Signal abnormalities on magnetic resonance imaging might therefore, at least in the early stages, represent reversible myelinolisis or cytotoxic edema associated with copper toxicity. The aim of this study was to evaluate the resolution of brain lesions in patients with Wilson’s disease during the long-term chelating therapy using magnetic resonance imaging and a possible signiifcance of the time latency between the initial symptoms of the disease and the introduction of this therapy. Initial magnetic resonance examination was performed in 37 patients with proven neurological form of Wilson’s disease with cerebellar, parkinsonian and dystonic presentation. Magnetic resonance reexamination was done 5.7 ± 1.3 years later in 14 patients. Patients were divided into: group A, where chelating therapy was initiated 〈 24 months from the ifrst symp-toms and group B, where the therapy started≥ 24 months after the initial symptoms. Symmetry of the lesions was seen in 100% of patients. There was a signiifcant difference between groups A and B regarding complete resolution of brain stem and putaminal lesions (P= 0.005 andP=0.024, respectively). If the correct diagnosis and adequate treatment are not established less than 24 months after onset of the symptoms, irreversible lesions in the brain parenchyma could be ex-pected. Signal abnormalities on magnetic resonance imaging might therefore, at least in the early stages, represent reversible myelinolisis or cytotoxic edema associated with copper toxicity.
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2014年第21期1912-1916,共5页 中国神经再生研究(英文版)
基金 supported by a grant from the Ministry of Science and Technological Development of Serbia,Scientific Project Number 175090
关键词 nerve regeneration Wilson’s disease diagnostic imaging chelating therapy magnetic resonance imaging delayed diagnosis metabolic disorders copper toxicity hepatic encephalopathy pontine myelinolysis cirrhosis neural regeneration nerve regeneration Wilson’s disease diagnostic imaging chelating therapy magnetic resonance imaging delayed diagnosis metabolic disorders copper toxicity hepatic encephalopathy pontine myelinolysis cirrhosis neural regeneration
  • 相关文献

参考文献45

  • 1Aisen AM, Martel W, Gabrielsen TO, Glazer GM, Brewer G, Young AB, Hill G (1985) Wilson disease of the brain: MR imaging. Radiology 157:137-141.
  • 2Ala A, Walker AR Ashkan K, Dooley JS, Schilsky ML (2007) Wilson's disease. Lancet 369:397-408.
  • 3Braffman BH (2000) The aging brain and neurodegenerative disorders. In: Neuroimaging. Clinical and Physical Principles (Zimmerman RA, Gibby WA, Cormody RF, eds), pp699-729. New York: Springer-Verlag.
  • 4Brewer G] (1995) Practical recommendations and new therapies for Wilson's disease. Drugs 50:240-249.
  • 5Yuzbasiyan--Gurkan V (1992) Wilson disease. Medicine Brewer GJ, 71:139-164.
  • 6Compston A (2009) Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinni- er Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509. Brain 132:1997-2001.
  • 7da Costa Mdo D, Spitz M, Bacheschi LA, Leite CC, Lucato LT, Barbosa ER (2009) Wilson's disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI. Neuroradiology 51:627-633.
  • 8Ferenci R Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F (2003) Diagnosis and phenotypic classifi- cation of Wilson disease. Liver Int 23:139-142.
  • 9Hancu A, Mihai MC, Axelerad AD (2011) Wilson's disease: a challeng- ing diagnosis. Clinical manifestations and diagnostic procedures in 12 patients. The Medical-Surgical lournal of the Physicians and Nat- uralists Society from Iasi 115:58-63.
  • 10Harper C, Butterworth R. Nutritional deficiencies and metabolic disor- ders (1992). In: Greenfield's Neuropathology (Greenfield JG, Hume Adams J, Duchen LW, eds). 5th ed., pp838-840. London, UK: Edward Arnold.

同被引文献8

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部